Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer

ConclusionNon-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients ’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research